Related Experiment Video
Updated: Mar 1, 2026

Author Spotlight: Exploring Huotan Jiedu Tongluo Decoction as an Antihypertensive Drug
Published on: May 17, 2024
Long-term pharmacologic treatment of women with hypertension
1Albert Einstein College of Medicine, Primary Care Clinic 3N3l, Bronx Municipal Hospital Center, Bronx, New York 10461.
Abstract:
As reviewed in "Hypertension in Women: What is Really Known?" (Women's Caucus Working Group on Women's Health of the Society of General Internal Medicine [1991] Ann Intern Med 115:287-293), the published literature reveals that hypertension frequently occurs in women and that only some prospective studies have defined specific benefits and risks of long-term pharmacologic treatment. Major U.S. epidemiologic studies show the incidence of hypertension to very between 20% and 50% of the population. It is more common among Afro-Americans than White Americans. Frequency increases with aging. Several studies of at least 3 years duration that have focused on the use of diuretics and B blockers are reviewed: Hypertension Detection and Follow-Up Program (HDFP), Medical Research Council (MRC), MRC trial in the treatment of older adults (MRC-Older), and isolated systolic hypertension in the elderly (SHEP). Both diuretics and B blockers generally lower blood pressure, and decrease stroke incidence and mortality. Diuretics seem to be more effective and better tolerated than B blockers. Long-term studies of newer antihypertensive agents do not yet exist. The sexual side effects of drugs have only been studied to a limited degree in women. © 1995 Wiley-Liss, Inc.
More Related Videos
Related Concept Videos
Hypertension IV: Drug Therapy and Lifestyle Modifications
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Hypertension V: Nursing Management
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...

